Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and is associated 25 with increased risks of hematological malignancies. While TP53 mutations have been 26 identified in CHIP, the molecular mechanisms by which mutant p53 promotes hematopoietic 27 stem and progenitor cell (HSPC) expansion are largely unknown. We discovered that mutant 28 p53 confers a competitive advantage to HSPCs following transplantation and promotes 29 HSPC expansion after radiation-induced stress. Mechanistically, mutant p53 interacts with 30 EZH2 and enhances its association with the chromatin, thereby increasing the levels of 31 H3K27me3 in genes regulating HSPC self-renewal and differentiation. Further, genetic and 32 pharmacological inhibition of EZH2 decrease the repopulating potential of p53 mutant 33
7 the impact of these p53 mutant proteins on HSPCs in vivo. We introduced p53 R248W , 110 p53 R273H , or p53 Y220C into WT HSPCs (CD45.2 + ) using retrovirus-mediated transduction, and 111 then transplanted transduced cells (GFP + ) together with competitor bone marrow (BM) cells 112 (CD45.1 + ) into lethally-irradiated recipient mice. We observed increased number of GFP + 113 cells in peripheral blood (PB) of recipient mice repopulated with HSPCs expressing mutant 114 p53 compared to that of control viruses transduced cells at 16 weeks following 115 transplantation ( Fig. 1f ). Increases in total GFP + cells in PB at 16 weeks from mice with 116 mutant p53 proteins were highly suggestive of enhanced HSPC repopulating potential. 117 p53 is important for HSC survival following genotoxic stress and p53 null HSCs are 118 less sensitive to irradiation as manifested by decreased apoptosis 20 . We found that ectopic 119 expression of p53 R248W , p53 R273H , or p53 Y220C in wild type HSPCs resulted in decreased 120 apoptosis following 2Gy irradiation ( Fig. 1g ), suggesting that HSPCs expressing these mutant 121 p53 proteins are not sensitive to radiation-induced stress. 122 123 TP53 mutations identified in CHIP confer a competitive advantage to HSPCs. Given that 124 codon 248 of the p53 protein (p53 R248 ) is most frequently mutated in CHIP, MDS, and AML 4, 125 6, 10-12, [18] [19] , we focused our investigation on p53 R248W in hematopoiesis. Since over-126 expression of mutant p53 from a MSCV promoter may not reflect accurate function when 127 expressed at physiological levels, we utilized the p53 R248W knock-in mice, where p53 R248W 128 was introduced into the humanized p53 knock-in (HUPKI) allele in mice, expressing human 129 p53 mutant protein from the endogenous murine Trp53 promoter 31 . The HUPKI allele 130 8 encodes a human/mouse chimeric protein consisting primarily of human p53 sequence 131 (amino acids 33-332) flanked by the conserved extreme amino and carboxyl-termini of 132 mouse p53 32 . HUPKI mice were described as p53 +/+ mice in the text. 133
Since the majority of TP53 mutations in CHIP are mono-allele missense mutations 134 ( Fig. 1b ) 4-6, 10-12 , we utilized heterozygous mutant mice (p53 R248W/+ ) to investigate the 135 biological impact of mutant p53 on primitive hematopoietic stem and progenitor cell 136 populations. As nonsense, frameshift, and splice site mutations result in TP53 deletions 14 , 137
we also included p53 +/and p53 -/mice in the experiments. We first analyzed the BM of 138 p53 +/+ , p53 +/-, p53 -/-, and p53 R248W/+ mice (8 to 12 week-old) and found that BM cellularity is 139 comparable among these mice ( Supplementary Fig. 1a ). We observed increased number of 140
LSKs and LT-HSCs in the BM of p53 -/mice as reported 20 ; however, p53 R248W affects neither 141 the frequency nor the number of hematopoietic stem and progenitors in the BM ( Fig. 2a,b,  142 and Supplementary Fig. 1b, 
c). While loss of p53 decreases the quiescence of LSKs and LT-143
HSCs 20 , mutant p53 does not affect HSPC quiescence (Fig. 2c,d ). In addition, we observed 144 similar number of apoptotic HSPCs in p53 +/+ , p53 +/-, p53 -/-, and p53 R248W/+ mice in steady state 145 ( Fig. 2e ). Thus, mutant p53 does not affect the frequency, quiescence, or the survival of 146
HSPCs when expressed at physiological levels. 147
While HSPCs harboring specific TP53 mutations may expand over time, it remains 148 unclear how different cellular stressors influence this expansion 4-6 . Hematopoietic 149 transplantation is a cellular stressor that has been shown to promote the expansion of mutant 150
HSPCs 12, 33-34 . We recently reported that p53 R248W enhances the repopulating potential of BM 151 cells 22 . To further establish that the enhanced repopulating potential is HSC intrinsic, we 152 purified HSCs (CD48 -CD150 + LSKs, CD45.2 + ) from p53 +/+ , p53 +/-, p53 -/-, and p53 R248W/+ mice 153 9 and performed HSC transplantation assays. Both p53 -/and p53 R248W/+ HSCs exhibited a 154 substantially higher contribution to PB production compared to p53 +/+ and p53 +/-HSCs at 20 155 weeks following primary transplantation (Fig. 2f ). In addition, the percentage of donor-derived 156 hematopoietic cells and HSPCs in the BM of recipient mice repopulated with p53 -/and 157 p53 R248W/+ HSCs was significantly higher than that of the p53 +/+ HSCs (Fig. 2g,h) . Mutant p53 158 did not affect myeloid and lymphoid differentiation in PB and the BM of recipient mice 159 following HSC transplantation ( Supplementary Fig. 1d,e ). 160
To determine the impact of mutant p53 on HSC self-renewal, we performed secondary 161 BM transplantation assays. We found that both p53 -/and p53 R248W/+ HSCs continue to show 162 enhanced engraftment compared to p53 +/+ and p53 +/-HSCs at 20 weeks following secondary 163 transplantation. Interestingly, p53 +/-HSCs show increased repopulating potential compared to 164 p53 +/+ HSCs in secondary transplantation assays ( Supplementary Fig. 1f ). We observed 165 increased number of donor-derived hematopoietic cells in the BM of secondary recipients 166 repopulated with p53 +/-, p53 -/-, and p53 R248W/+ cells compared to p53 +/+ cells (Supplementary 167 Fig. 1g ). However, neither TP53 mutation nor deletionp53-deficiency alters terminal 168 differentiation of HSCs ( Supplementary Fig. 1h ). 169
To enumerate the numbers of functional HSCs in the BM of p53 R248W/+ mice, we 170 performed competitive BM transplantation experiments with limiting-dilution of donor cells. 171
The frequency of competitive repopulation units (CRU) in the BM of p53 R248W/+ mice is 3 to 4 172 fold higher than that of the p53 +/+ mice (Fig. 2i,j) . Enhanced repopulating potential of 173 p53 R248W/+ BM cells could be due to changes in homing capacities of donor cells. We 174 performed homing assays but did not detect difference in the frequency of donor-derived cells 175 in the BM of recipient mice repopulated with p53 R248W/+ BM cells compared to p53 +/+ BM cells 176 ( Supplementary Fig. 1i ,j). Taken together, we demonstrate that mutant p53 identified in CHIP 177 confers a competitive advantage to HSPCs following transplantation. 178 179 TP53 mutations identified in CHIP confer a survival advantage to HSPCs after 180 radiation-induced stress. Therapy-related CHIP in patients with non-hematologic cancers is 181 common and associated with adverse clinical outcomes 10, 12 . Cytotoxic therapy results in the 182 expansion of clones carrying TP53 mutations 10, 12, 35 . Indeed, we found that chemotherapy 183 treatment expands HSPCs expressing mutant p53 22 . Given that HSPCs expressing mutant 184 p53 are not sensitive to radiation (Fig. 1g ), we then examined the impact of radiation on 185 mutant HSPC expansion. We generated mixed BM chimaeras containing both p53 R248W/+ 186 (CD45.2 + ) and p53 +/+ (CD45. 1 + ) cells with a 1:10 ratio of mutant to WT cells. Eight weeks 187 following transplantation, recipient mice were treated with or without 5Gy total body irradiation 188 (TBI) ( Fig. 3a ). We found that mutant BM cells outcompeted p53 +/+ cells, and became clonal 189 dominance following TBI (Fig. 3b ). Further, TBI significantly increased frequency of mutant 190
HSPCs in BM of recipient mice ( Fig. 3c,d) . Thus, we demonstrate that radiation promotes the 191 expansion of HSPCs with mutant p53. 192
To determine the impact of radiation on p53 +/+ and p53 R248W/+ mice, we irradiated these 193 mice and monitored their survival. While most p53 +/+ mice died 5 weeks following 9Gy TBI, 194 most p53 R248W/+ mice were still alive ( Supplementary Fig. 2a ). Further, p53 R248W/+ HSCs show 195 decreased apoptosis both in vitro and in vivo following 2Gy irradiation ( Fig. 3e ,f). Using 196 phosphorylation of histone H2AX (γH2AX) as an indicator of DNA damage, we found that 197 p53 +/+ HSCs stained positive for γH2AX, whereas p53 R248W/+ HSCs were largely devoid of 198 γH2AX foci ( Supplementary Fig. 2b,c) . These data suggest that p53 R248W/+ HSCs are less 199 sensitive to radiation-induced DNA damage compared to p53 +/+ HSCs. 200
To determine the impact of radiation on p53 R248W/+ HSPC function in vivo, we treated 201 p53 +/+ and p53 R248W/+ mice with 2Gy TBI. Two hours following TBI, we isolated live BM cells 202 from irradiated mice and performed competitive transplantation assays. Irradiated mutant BM 203 cells displayed enhanced repopulating potential in primary transplantation assays compared 204 to irradiated WT cells ( Fig. 3g ). We observed increased number of donor-derived HSPCs in 205 the BM of primary recipient mice repopulated with live p53 R248W/+ BM cells ( Fig. 3h and 206 Supplementary Fig. 2d ). We then transplanted 3 x 10 6 BM cells isolated from the primary 207 recipient mice into lethally irradiated secondary recipients. Sixteen weeks after secondary 208 transplantation, p53 R248W/+ cells continued to show increased repopulating ability ( Fig. 3i ). 209
While mutant p53 had no effect on multi-lineage differentiation in peripheral blood of primary 210 recipient mice ( Supplementary Fig. 2e ), we found decreased myeloid differentiation and 211 increased B cell differentiation in the PB of secondary recipient mice repopulated with mutant 212 BM cells ( Fig. 3j ). Thus, we demonstrate that TP53 mutations identified in CHIP confer 213 resistance to radiation, leading to the selective expansion of TP53-mutant HSPCs. 12 215 HSC and AML signatures were enriched in p53 mutant HSPCs. Wild-type p53 is a 216 transcription factor that activates the transcription of several target genes in HSCs, including 217 p21 and Necdin 20-21 . However, we found that mutant p53 does not alter the expression of 218 p21 and Necdin in HSCs (Fig.4a ). To understand how mutant p53 enhances HSPC self-219 renewal, we performed transcript profiling (using RNA-seq studies and quantitative real-time 220 PCR analysis) to compare gene expression in HSPCs isolated from p53 +/+ and p53 R248W/+ 221 mice. We employed Gene Set Enrichment Assays (GSEA) to group potential mutant p53 222 target genes into specific pathways important in HSPC behavior. HSC and AML signatures 223 were significantly enriched in p53 mutant HSPCs compared to p53 +/+ HSPCs (Supplementary 224 Supplementary Fig. 3c ). Collectively, the gene expression profiling data 228 suggest that mutant p53 modulates specific pathways associated with HSC maintenance and 229 leukemogenesis. 230 231 EZH2 targets were significantly downregulated in p53 mutant HSPCs. While we found 232 that several hundred genes are either upregulated or downregulated in p53 mutant HSPCs 233 compared to WT HSPCs (data not shown), how mutant p53 regulates gene expression in 234 13 HSPCs is unknown. Recent studies revealed that some mutant p53 proteins increase the 235 expression of epigenetic factors, including MLL1, MLL2, and MOZ (KAT6A), in human cancer 236 cells 36 . MLL1 and MLL2 are key components of the MLL complexes that confer histone 237 H3K4 trimethylation (H3K4me3), which is an active histone mark important for gene 238 expression 37-38 . MOZ is a histone acetyltransferase and mediates histone H3K9 acetylation 239 (H3K9ac) [39] [40] . However, we found that the expression of MLL1, MLL2, and MOZ is 240 comparable in p53 WT and mutant HSPCs ( Supplementary Fig. 3d ), suggesting mutant p53 241 may utilize other mechanisms to modulate gene expression in hematopoietic cells. 242
Interestingly, we found that Ezh2 target genes are significantly downregulated in 243 p53 R248W/+ HSPCs compared to p53 +/+ HSPCs (Fig. 4b ). EZH2 is a key component of the 244 PRC2 complex that catalyzes the methylation of histone H3K27me3, a repressive histone 245 mark 25 . Western blot analysis showed increased levels of H3K27me3 in p53 mutant HSPCs 246 compared to WT HSPCs (Fig. 4c ). Further, p53 R248W/+ HSCs displayed higher levels of 247
H3K27me3 compared to p53 +/+ HSCs quantified by flow cytometry analysis ( Fig. 4d ). 248
To further understand how mutant p53 modulates gene expression in hematopoietic 249 cells, we performed H3K27me3 ChIP-seq assays in HSPCs from p53 +/+ and p53 R248W/+ mice. 250
As expected, H3K27me3 is enriched at the transcription start site (TSS). Large regions of 251
H3K27me3 enrichments are also found covering entire gene regions as well as intragenic 252 regions. We found that p53 mutant HSPCs exhibited significantly higher levels of H3K27me3 253 at TSS (blue sample) compared to that of the WT HSPCs (black sample) ( Fig. 4e ). The heat 254 map of H3K27me3 ChIP-seq also revealed that many genes show increased H3K27me3 255 enrichment in mutant HSPCs compared to that of the WT HSPCs ( Fig. 4f) . 256
Genome-wide H3K27me3 occupancy and GREAT pathway analysis revealed that 257 p53 R248W/+ cells showed non-overlapping H3K27me3 peaks in genes that positively regulate 258 cell differentiation ( Supplementary Fig. 3e ), whereas p53 +/+ cells had non-overlapping 259
H3K27me3 peaks in genes important for stem cell proliferation ( Supplementary Fig. 3f ). 260
Indeed, increased levels of H3K27me3 were found in genes regulating HSC self-renewal and 261 differentiation, including Cebpα and Gadd45g 41-43 , in p53 R248W/+ HSPCs compared to p53 +/+ 262 HSPCs ( Fig. 4f ,g). The transcription factor C/EBP alpha is required for granulopoiesis and 263 frequently disrupted in human AML. Loss of Cebpα enhances HSC repopulating capability 264 and self-renewal 41-42 . Tumor suppressor GADD45G induces HSC differentiation following 265 cytokine stimulation, whereas loss of GADD45G enhances the self-renewal potential of HSCs 266 43 . We confirmed that there were increased levels of H3K27me3 at both Cebpα and Gadd45g 267 genes by ChIP experiments (Fig. 4h ). Consistently, both Cebpα and Gadd45g were 268 significantly downregulated in p53 R248W/+ HSCs compared to p53 +/+ HSPCs (Fig. 4i,j) . 269
Stimulation of WT HSPCs with thrombopoietin (TPO) dramatically increased Gadd45g 270 expression, however TPO treatment only modestly increased Gadd45g expression in p53 271 mutant HSPCs ( Supplementary Fig. 3g ), suggesting that mutant p53 may repress Gadd45g 272 expression upon cytokine stimulation. To determine the impact of Gadd45g on HSPC 273 function in vitro, we introduced Gadd45g into BM cells from p53 +/+ and p53 R248W/+ mice using 274 retroviruses and performed colony formation assays. We found that ectopic Gadd45g 275 expression decreases the colony formation of p53 mutant BM cells ( Supplementary Fig. 3h ). 276
These data suggest that mutant p53 may repress gene expression in HSPCs through 277 increasing the levels of H3K27me3. 278 279
Mutant p53 interacts with EZH2 and enhances its association with the chromatin in 280
HSPCs. We next investigated the mechanisms by which mutant p53 enhances H3K27me3 in 281
HSPCs. The PRC2 complex consists of EZH2/EZH1, EED, and SUZ12 25 . While the levels of 282 EZH2 was modestly increased in mutant HSPCs, the expression of other PRC2 core 283 components was comparable between p53 WT and mutant HSPCs ( Supplementary Fig. 4a ). 284
As the protein levels of PRC2 complex in mouse HSPCs were very low (data not shown), we 285 determined the impact of mutant p53 on the expression of PRC2 complex in murine 286 hematopoietic progenitor 32D cells. We found that ectopic expression of mutant p53, but not 287 WT p53, increased levels of H3K27me3 in 32D cells ( Fig. 5a ). However, ectopic expression 288 of neither WT nor mutant p53 affected the protein levels of PRC2 core components in 32D 289 cells ( Supplementary Fig. 4b ). Thus, the increased H3K27me3 in p53 mutant HSPCs may 290 not be due to increased expression of catalytic components of PRC2, including EZH2 and 291 EZH1, or other components of the PRC2 complex. 292
We then tested whether mutant p53 interacts with EZH2. We performed co-293 immunoprecipitation assays and found that several mutant p53 proteins, including p53 R248W , 294 p53 R273H , and p53 R175H , displayed enhanced association with EZH2 compared to WT p53 295 ( Fig. 5b) . The recruitment and displacement of the PRC2 complex on chromatin are a 296 dynamic process and tightly regulated to activate or repress transcription 23-26 . Genome wide 297
H3K27me3 ChIP-seq assays revealed that the majority of H3K27me3 peaks in p53 mutant 298
HSPCs are overlapped with that of the WT HSPCs ( Fig. 4e,f ), suggesting that mutant p53 299 may enhance the association of EZH2 with the chromatin, thereby increasing the levels of 300
H3K27me3. To test this, we examine the co-localization of p53 and Ezh2 in p53 WT and 301 mutant HSPCs utilizing the ImageStream flow cytometry analysis. The median fluorescent 302 intensity (MFI) of p53 and Ezh2 in the nucleus was comparable between p53 +/+ and 303 p53 R248W/+ HSPCs ( Supplementary Fig. 4c,d ). However, we found that mutant p53, but not 304 WT p53, show increased co-localization with Ezh2 in the nucleus (Fig. 5c,d ). To determine 305 whether mutant p53 enhances the association of Ezh2 with the chromatin, we separated 306 proteins in p53 WT and mutant HSPCs into nuclear soluble and chromatin bound fractions. 307
We observed increased levels of Ezh2 in the chromatin bound faction of p53 mutant HSPCs 308 compared to that of the p53 WT HSPCs (Fig. 5e ). Thus, we demonstrate that mutant p53 309 interacts with EZH2 and enhances its association with the chromatin, thereby increasing the 310 levels of H3K27me3 in HSPCs. 311
312
Genetic and pharmacological inhibition of EZH2 decrease the repopulating potential of 313 p53 mutant HSPCs. Hematopoietic-specific deletion of Ezh2 impairs HSC self-renewal and 314 terminal differentiation 28 . To determine the functional impacts of mutant p53 and Ezh2 315 interaction on hematopoiesis, we generated p53 R248W/+ Ezh2 f/f -Mx1Cre + mice 28 . While Ezh2-316 deficiency did not affect Cebpα and Gadd45g expression, Ezh2 deficiency brought the 317 expression of Cebpα and Gadd45g back to normal in the mutant p53 background ( Fig.6a and 318 Supplementary Fig. 5a ). 319
To determine the impact of genetic inhibition of Ezh2 on p53 mutant HSPC function in 320 vitro, we performed serial replating assays using BM cells from p53 +/+ , Ezh2 f/+ -Mx1Cre + , 321 p53 R248W/+ and p53 R248W/+ Ezh2 f/+ -Mx1Cre + mice following pI:pC treatment. We found that 322
Ezh2-deficiency brings the replating potential of p53 mutant BM cells back to the WT cell 323 level ( Fig. 6b ). To determine the impact of Ezh2 deficiency on HSPC function in vivo, we 324 transplanted 250,000 donor BM cells (CD45.2 + ) into lethally irradiated recipient mice 325 (CD45.1 + CD45.2 + ) along with 500,000 WT competitor BM cells (CD45.1 + ). We treated 326 recipient mice with pI:pC at 8 weeks after transplantation to delete Ezh2 and then examined 327 donor cell engraftment every 4 weeks for 20 weeks. p53 R248W/+ BM cells exhibited a 328 substantially higher contribution to PB production compared to p53 +/+ cells at 20 weeks 329 following pI:pC treatment, whereas loss of Ezh2 decreased the engraftment of mutant BM 330 cells to the WT cell level (Fig. 6c ). While both the frequency and the absolute number of 331 donor-derived HSPCs in the BM of recipient mice repopulated with p53 R248W/+ BM cells was 332 significantly higher than that of the WT cells, the frequency and the number of donor-derived 333
HSPCs in the BM of recipient mice repopulated with p53 +/+ and p53 R248W/+ Ezh2 -/-BM cells 334
were comparable ( Fig. 6d,e ). In addition, we observed decreased number of donor-derived 335
CMPs and MEPs in the BM of recipient mice repopulated with p53 R248W/+ Ezh2 -/-BM cells 336 compared to that of the p53 R248W/+ BM cells ( Supplementary Fig. 5b,c) , whereas the number 337 of donor-derived GMPs was comparable in the BM of recipient mice p53 R248W/+ cells and 338 p53 R248W/+ Ezh2 -/cells ( Supplementary Fig. 5d ). To determine the impact of Ezh2-deficiency 339 on mutant HSC self-renewal, we performed secondary BM transplantation assays and found 340 that EZH2-deficiency decreases the repopulating potential of p53 R248W/+ HSCs following 341 secondary transplantation assays (Fig. 6f) . 342
To determine the effect of pharmacological inhibition of Ezh2 activity on mutant p53 343 HSPCs, we treated p53 +/+ and p53 R248W/+ BM cells with DMSO or EZH2 specific inhibitor 344 EPZ011989 44 and performed serial replating assays. While EZH2 inhibitor had no effect on 345 the colony formation of WT BM cells, EZH2 inhibitor treatment decreased the replating 346 potential of p53 R248W/+ BM cells to the WT level ( Fig. 6g However, we found that mutant p53 does not alter the expression of p53 target genes, 361
including p21 and Necdin, in HSCs (Fig. 4a ). Genome-wide transcriptome assays revealed 362 that HSC and AML signatures are enriched in p53 mutant HSPCs, which is different from 363 gene expression signatures regulated by the wild type p53 protein 20, 45 . Thus, our findings 364 provide experimental evidence that TP53 mutations identified in CHIP regulate gene 365 expression in a distinct manner compared to WT p53. 366
Some mutant p53 proteins have been shown to promote cancer development through 367 modulating gene transcription 14 . Dysregulated epigenetic control has been implicated in HSC 368 aging and the pathogenesis of hematological malignancies 16, 46-48 . Recent studies showed 369 that some mutant p53 proteins increase the expression of epigenetic factors, including MLL1, 370 MLL2, and MOZ, in human cancer cells 36 . However, we found that mutant p53 does not 371 affect the expression of these genes in HSPCs, suggesting mutant p53 proteins may 372 modulate gene expression through other mechanisms in HSPCs. 373
RNA-seq assays revealed that Ezh2 target genes are significantly downregulated in 374 p53 R248W/+ HSPCs compared to p53 +/+ HSPCs. We observed increased levels of H3K27me3 375 in p53 mutant HSPCs. Further, H3K27me3 ChIP-seq assays revealed that p53 mutant 376
HSPCs exhibit significantly high levels of H3K27me3. Genes important for HSC self-renewal 377 and differentiation, including Cebpα and Gadd45g 41-43 , were occupied with increased levels 378 20 of H3K27me3 in p53 mutant HSPCs. Thus, mutant p53 may enhance HSPC self-renewal 379 through increasing the levels of H3K27me3 in genes involved in HSC self-renewal and 380 differentiation. 381
Then, how does mutant p53 enhances H3K27me3 in HSPCs? One possible 382 mechanism is that mutant p53 upregulates the expression of the core PCR2 components, 383 thereby increasing PRC2 activity. However, the expression of the core PRC2 components 384 was comparable between p53 WT and mutant HSPCs. We discovered that several mutant 385 p53 proteins show enhanced association with EZH2 compared to WT p53. Genome wide 386
H3K27me3 ChIP-seq assays showed that the majority of H3K27me3 peaks in p53 mutant 387
HSPCs are overlapped with that of the WT HSPCs, suggesting that mutant p53 may enhance 388 the association of EZH2 with the chromatin in HSPCs, thereby increasing H3K27me3. 389
Indeed, we observed enhanced association of Ezh2 with the chromatin in p53 mutant HSPCs 390 compared to WT HSPCs. Considering that common mutations identified in CHIP affect 391 epigenetic modulators, including DNMT3A, ASXL1, and TET2 4-6 , our findings underscore the 392 importance of dysregulated epigenetic control in CHIP development. Clinical studies revealed that hematopoietic clones harboring specific mutations in 405 individuals with CHIP may expand over time 4-6 . However, how different cellular stressors 406 affect clonal expansion is largely unknown. Recently, two different stressors, including 407 hematopoietic transplantation and cytotoxic therapy have been shown to expand 408 hematopoietic clones 10, 12, 22, 33-35 . We discovered that TP53 mutations identified in CHIP 409 confer a competitive advantage to HSPCs following transplantation. TP53 mutations are 410 associated with prior exposure to chemotherapy 10, 12 and we observed that TP53 mutations 411 confer radiation resistance, leading to selective expansion of TP53-mutant HSPCs. Recently, 412 PPM1D mutations were found in CHIP, especially in patients previously exposed to 413 chemotherapy 10, 12, 33-34 . PPM1D is a phosphatase that negatively regulates p53 and several 414 proteins involved in the DNA damage response (DDR) pathway 49-50 . While PPM1D mutations 415 result in the expansion of PPM1D-mutant hematopoietic cells following chemotherapy 416 treatment 33-34 , they do not confer competitive advantage to HSPCs following bone marrow 417 transplantation 12, 33-34 . Thus, p53 and PPMID appear to play distinct roles in driving clonal 418
hematopoiesis. 419
While we have identified a stem cell intrinsic mechanism by which mutant p53 drives 420 clonal hematopoiesis, recent studies indicate that mutations identified in CHIP may utilize cell 421 extrinsic mechanisms to promote clonal hematopoiesis 51-52 . For example, mutant 422 hematopoietic cells displayed increased secretion of pro-inflammatory cytokines such as IL-423 1β and IL-6 51-52 . Since some inflammatory response genes are upregulated in p53 mutant 424
HSPCs (data not shown), we will investigate the cell extrinsic mechanisms by which mutant 425 p53 drives CHIP in the future. 426
In summary, we discovered that TP53 mutations drive clonal hematopoiesis in response 427 to distinct cellular stressors. Mechanistically, mutant p53 interacts with EZH2 and enhances 428 its association with the chromatin, increasing the levels of H3K27me3 in genes regulating 429 HSPC self-renewal and differentiation. EZH2 is rarely mutated in CHIP 4-6 and we found that 430 genetic and pharmacological inhibition of EZH2 decrease the repopulating potential of p53 431 mutant HSPCs. Thus, our work will likely establish epigenetic regulator EZH2 as a novel 432 therapeutic target for preventing CHIP progression and treating hematological malignancies 433 with TP53 mutations. 434
Methods. 435 436
Mice. The HUPKI (p53 +/+ ) and p53 R248W/+ mice used in our studies have been backcrossed to 437 the C57BL6 background for 12 generations 22,31 . All young p53 +/+ , p53 +/-, p53 -/-, and 438 p53 R248W/+ and Ezh2 F/F -Mx1-Cre + mice used in these studies are 8 to 12 weeks old and are 439 tumor free. Wild type C57BL/6 (CD45.2 + ), B6.SJL (CD45.1 + ) and F1 mice (CD45.2 + CD45.1 + ) 440 mice were obtained from an on-site core breeding colony. All mice were maintained in the 441
Indiana University Animal Facility according to IACUC-approved protocols. 442 To quantify the intensity of H3K27me3 in HSPCs, lineage-depleted BM cells were first 510 stained with antibodies against HSPC surface markers, then fixed and permeabilized using 511 26 the Cytofix/Cytoperm Kit (BD Biosciences), as described by the manufacturer, and finally 512 stained with an Alexa-488-conjugated anti-H3K27me3. 513
Generation of retroviruses and infection of hematopoietic stem and progenitor cells. 443
For quantitative image analysis of p53 and Ezh2 co-localization within the nucleus, 514 fluorescent cell images (×40) were acquired using an ImageStream flow cytometry system 515 (Amnis; Seattle, WA, http://www.amnis.com) 26. Between 171-554 Lin -Sca1 + cKit + CD150 + cell 516
images were analyzed per sample using IDEAS software (Amnis; Seattle, WA, 517 http://www.amnis.com). In focus cells were evaluated after gating on live, single, Lin -518 Sca1 + cKit + CD150 + cells. Utilizing DAPI staining, we were able to create a nucleus mask and 519 instruct the program to only look at the staining of p53 and Ezh2 within the DAPI/nucleus 520 mask. Bright detail intensity of FITC-p53, PE-Ezh2, and DAPI staining was used to quantify 521 mean and geo mean intensity and co-localization within the nucleus. A similarity feature 522 determined the amount of overlay between p53 and Ezh2 within the DAPI mask. The higher 523 the similarity score is, the more co-localized the staining within the nucleus. 524
Co-IP. Co-Immunoprecipitation (Co-IP) experiments were performed as described previously 525 with certain modifications 53 . H1299 cells (p53 null) were co-transfected with FLAG-HA-EZH2 526 and WT or mutant p53, respectively, or transfected with FLAG-HA-EZH2 alone. Nuclear 527 extract (NE) was prepared from these cells and incubated with a polyclonal p53 antibody 528 (FL393, Santa Cruz) prior to addition of protein G beads. After overnight incubation, beads 529 were then washed 5 times and eluted with glycine (0.1 M, pH 2.0), and then neutralized by 530 adding Tris solution (1.5 M, pH 8.8). The eluates were mixed with SDS sample buffer and 531 analyzed by SDS-PAGE, followed by immunoblotting. 532 Cellular fractionation. Cellular fractionation was performed as described previously with 533 modifications 54 . Briefly, p53 +/+ and p53 R248W/+ HSPCs were harvested and lysed in Buffer A 534 (10 mM Tris-HCl, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, 1 μg/ml 535 Pepstatin A, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin). The cell lysate was then homogenized by 536 a dounce homogenizer for 10 strokes and centrifuged at 4 °C and 15,000 × g for 10 min. The 537 pellet was washed with Buffer A and then re-suspended with Buffer C (20 mM Tris-HCl, 538 pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM 539 PMSF, 1 μg/ml Pepstatin A, 1 μg/ml Leupeptin, 1 μg/ml Aprotinin) and dounced for 10 540 strokes. Suspension was rotated at 4 °C for 30 min and centrifuged at 4 °C and 7,500 × g for 541 5 min. The supernatant was collected as the nucleoplasmic fraction. The pellet was saved as 542 the chromatin fraction and re-suspended with Buffer C. Cell fractions were mixed with SDS 543 sample buffer and heated at 95 °C for 5 min. Whole cell extraction, nucleoplasmic, and 544 chromatin extractions were sonicated for 15 sec using a probe sonicator before loading to 545 SDS-PAGE. 546
RNA sequencing. Total RNA is extracted from LSKs using RNeasy MicroPlus Kit (Qiagen). 547
Then the mRNA is enriched with the oligo(dT) magnetic beads (for eukaryotes), and is 548 fragmented into short fragments (about 100 bp). With random hexamer-primer, the first 549 strand of cDNA is synthesized, and then the second strand is synthesized. The double strand 550 cDNA is purified with magnetic beads. The ends of the double strand cDNA are repaired, and 551 Gene sets with FDR q-value < 0.05 were considered significantly enriched. 560
ChIP sequencing. Lin -Kit + cells were fixed with 1% formaldehyde for 15 min and quenched 561 with 0.125 M glycine. Chromatin was isolated by the addition of lysis buffer, followed by 562 disruption with a Dounce homogenizer. Lysates were sonicated and the DNA sheared to an 563 average length of 300-500 bp. Genomic DNA (Input) was prepared by treating aliquots of 564 chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol 565 precipitation. Pellets were resuspended and the resulting DNA was quantified on a NanoDrop 566
spectrophotometer. An aliquot of chromatin (30 µg) was precleared with protein A agarose 567 beads (Invitrogen). Genomic DNA regions of interest were isolated using 4 ug of antibody 568 against Histone H3K27me3 (clone: 39155, Active Motif) Complexes were washed, eluted 569 from the beads with SDS buffer, and subjected to RNase and proteinase K treatment. 570
Crosslinks were reversed by incubation overnight at 65 °C, and ChIP DNA was purified by 571 phenol-chloroform extraction and ethanol precipitation. 572
Illumina sequencing libraries were prepared from the ChIP and Input DNAs by the 573 standard consecutive enzymatic steps of end-polishing, dA-addition, and adaptor ligation. 574
After a final PCR amplification step, the resulting DNA libraries were quantified and 575 sequenced on Illumina's NextSeq 500 (75 nt reads, single end). Reads were aligned to the 576 mouse genome (mm10) using the BWA algorithm (default settings). Duplicate reads were 577 removed and only uniquely mapped reads (mapping quality >= 25) were used for further 578 analysis. Alignments were extended in silico at their 3'-ends to a length of 200 bp, which is 579 the average genomic fragment length in the size-selected library, and assigned to 32-nt bins 580 along the genome. The resulting histograms (genomic "signal maps") were stored in bigWig 581 files. H3K27me3 enriched regions were identified using the SICER algorithm with a MaxGap 582 29 parameter setting of 600 bp. Signal maps and peak locations were used as input data to 583 Active Motifs proprietary analysis program, which creates Excel tables containing detailed 584 information on sample comparison, peak metrics, peak locations and gene annotations. Student's t test where applicable for comparison between two groups, and a One-way 590 ANOVA test was used for experiments involving more than two groups. Statistical 591 significance was defined as *P<0.05, **P<0.01, ***P<0.001, ****P< 0.0001, ns, not significant. 
